Research Papers:

Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study

Anjali Gupta, Taofik Oyekunle, Omolola Salako, Adetola Daramola, Olusegun Alatise, Gabriel Ogun, Adewale Adeniyi, April Deveaux, Veeral Saraiya, Allison Hall, Omobolaji Ayandipo, Thomas Olajide, Olalekan Olasehinde, Olukayode Arowolo, Adewale Adisa, Oludolapo Afuwape, Aralola Olusanya, Aderemi Adegoke, Trygve O. Tollefsbol, Donna Arnett, Michael J. Muehlbauer, Christopher B. Newgard, H3 Africa Kidney Research Network and Tomi Akinyemiju _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2021; 12:1230-1242. https://doi.org/10.18632/oncotarget.27991

Metrics: PDF 700 views  |   Full Text 5118 views  |   ?  


Anjali Gupta1,2, Taofik Oyekunle2, Omolola Salako3, Adetola Daramola3, Olusegun Alatise4, Gabriel Ogun5, Adewale Adeniyi6, April Deveaux2, Veeral Saraiya7, Allison Hall8, Omobolaji Ayandipo5, Thomas Olajide3, Olalekan Olasehinde4, Olukayode Arowolo4, Adewale Adisa4, Oludolapo Afuwape5, Aralola Olusanya5, Aderemi Adegoke9, Trygve O. Tollefsbol10, Donna Arnett11, Michael J. Muehlbauer12, Christopher B. Newgard12, H3 Africa Kidney Research Network13 and Tomi Akinyemiju2,14,15

1 Trinity College of Arts and Sciences, Duke University, Durham, NC, USA

2 Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC, USA

3 College of Medicine & Lagos University Teaching Hospital, University of Lagos, Lagos State, Nigeria

4 Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun State, Nigeria

5 University College Hospital, University of Ibadan, Ibadan, Oyo State, Nigeria

6 Federal Medical Center, Abeokuta, Ogun State, Nigeria

7 Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC, USA

8 Department of Pathology, School of Medicine, Duke University, Durham, NC, USA

9 Our Lady of Apostle Catholic Hospital, Ibadan, Oyo State, Nigeria

10 Department of Biology, College of Arts and Sciences, University of Alabama at Birmingham, AL, USA

11 College of Public Health, University of Kentucky, Lexington, KY, USA

12 Duke Molecular Physiology Institute, Duke University, Durham, NC, USA

13 Department of Internal Medicine, School of Medicine, University of Kansas Medical Center, Kansas City, KS, USA

14 Duke Cancer Institute, School of Medicine, Duke University, Durham, NC, USA

15 Duke Global Health Institute, Duke University, Durham, NC, USA

Correspondence to:

Tomi Akinyemiju,email: [email protected]

Keywords: C-reactive protein; breast cancer; Nigeria; molecular subtype; menopausal status

Received: May 14, 2021     Accepted: June 02, 2021     Published: June 22, 2021

Copyright: © 2021 Gupta et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Breast cancer (BC) in Nigeria is characterized by disproportionately aggressive molecular subtypes. C-reactive protein (CRP) is associated with risk and aggressiveness for several types of cancer. We examined the association of high-sensitivity CRP (hsCRP) with odds of BC by molecular subtype among Nigerian women. Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the association between hsCRP and odds of BC overall and by molecular subtype (luminal A, luminal B, HER2-enriched and triple-negative or TNBC). High hsCRP (> 3 mg/L) was observed in 57% of cases and 31% of controls and was associated with 4 times the odds of BC (aOR: 4.43; 95% CI: 2.56, 7.66) after adjusting for socio-demographic, reproductive, and clinical variables. This association persisted regardless of menopausal status and body mass index (BMI) category. High hsCRP was associated with increased odds of TNBC (aOR: 3.32; 95% CI: 1.07, 10.35), luminal A BC (aOR: 4.03; 95% CI: 1.29, 12.64), and HER2-enriched BC (aOR: 6.27; 95% CI: 1.69, 23.25). Future studies are necessary in this population to further evaluate a potential role for CRP as a predictive biomarker for BC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27991